Ipsen 경영진
경영진 기준 점검 4/4
Ipsen CEO는 David Loew, Jul2020 에 임명되었습니다 의 임기는 5.83 년입니다. 총 연간 보상은 €4.77M, 21.5% 급여 및 78.5% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 €13.75M 가치에 해당하는 회사 주식의 0.11% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5 년과 11 년입니다.
핵심 정보
David Loew
최고경영자
€4.8m
총 보수
| CEO 급여 비율 | 21.48% |
| CEO 재임 기간 | 5.8yrs |
| CEO 지분 보유율 | 0.1% |
| 경영진 평균 재임 기간 | 5yrs |
| 이사회 평균 재임 기간 | 11yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • May 17
IPN: Future Portfolio Execution And Core Pipeline Will Shape Re Rated Earnings Potential
Analysts have raised Ipsen's price target by €13 to €183, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E that align with recent upward revisions from major banks. Analyst Commentary Recent research updates point to a more constructive stance on Ipsen, with several bullish analysts revisiting their models and price targets.내러티브 업데이트 • Apr 24
IPN: Future Portfolio Execution Will Drive Re Rated Earnings Power Potential
Narrative Update on Ipsen The analyst fair value estimate for Ipsen has been revised from €155 to €183. This reflects analysts' updated assumptions on higher revenue growth, a different discount rate, a higher future P/E and recent price target increases and rating changes across several banks.
내러티브 업데이트 • Apr 10
IPN: Oncology Pipeline Progress And Safety Setbacks Will Shape Balanced Future Outlook
Analysts have adjusted the Ipsen price target to €151.94, with recent research pointing to updated revenue growth and profit margin assumptions, as well as fresh Street targets around €160 and €170 as key drivers of the new view. Analyst Commentary Bullish Takeaways Bullish analysts are pointing to higher price targets around €160 and €170, which reflects confidence in Ipsen’s ability to execute on its current pipeline and financial framework despite recent product-specific issues.내러티브 업데이트 • Mar 27
IPN: Early Oncology Pipeline And Safety Setbacks Will Shape Future Upside
The analyst fair value estimate for Ipsen has shifted from €143 to about €152, as analysts factor in updated price targets around €160 to €170 and recent rating changes that reflect both the impact of the tazemetostat withdrawal and a focus on the broader pipeline and earnings profile. Analyst Commentary Recent research shows a split view on Ipsen, with some bullish analysts lifting price targets toward €160 to €170, while more cautious voices highlight pipeline depth and valuation risks after the tazemetostat withdrawal.
내러티브 업데이트 • Mar 13
IPN: Oncology Setbacks And Limited Late Stage Pipeline Will Constrain Future Upside
The analyst fair value estimate for Ipsen has shifted from €105 to €115, with analysts pointing to recent price target revisions, mixed views on the company’s pipeline depth, and updated assumptions on margins and future P/E levels as key drivers of the change. Analyst Commentary Recent Street research around Ipsen has focused on shifting views of the company’s pipeline and valuation, with mixed reactions to the withdrawal of tazemetostat and differing opinions on the depth of late stage assets.내러티브 업데이트 • Feb 27
IPN: Limited Late Stage Pipeline Will Constrain Future Upside Potential
The analyst fair value estimate for Ipsen has moved from €134.80 to €143.00, reflecting updated assumptions on revenue growth, margins, and future P/E, following recent price target changes from banks that now range from about €125 to €170. Analyst Commentary Recent research on Ipsen reflects a mix of optimism and caution, with target prices clustering between about €125 and €170 and ratings spread across Buy, Neutral, and Equal Weight.내러티브 업데이트 • Feb 12
IPN: Competitive Pressures And Thin Pipeline Will Shape A Balanced Outlook
Analysts have increased their fair value estimate for Ipsen to about €135 per share from roughly €133, reflecting updated price targets that incorporate a mix of cautious views on the late stage pipeline and concerns around competitive pressures, alongside modest target increases from others. Analyst Commentary Recent research shows a split view on Ipsen, with some analysts trimming expectations and others nudging targets higher.내러티브 업데이트 • Jan 29
IPN: Mixed Ratings And Limited Late Stage Assets Will Shape A Balanced Outlook
Narrative Update The updated analyst price target for Ipsen moves modestly higher to about €133 from about €131. Analysts point to slightly stronger revenue growth and margin assumptions, while also flagging ongoing concerns about limited late stage assets and competitive pressure on Somatuline, as reflected in recent mixed rating and target changes from UBS, Barclays, and BNP Paribas Exane.내러티브 업데이트 • Jan 15
IPN: Mixed Ratings And Pipeline Setbacks Will Shape A Cautious Yet Balanced Outlook
Our updated fair value estimate for Ipsen edges up from €130.07 to €130.79. This reflects a blend of mixed Street signals, where some analysts point to valuation constraints and pipeline depth, while others lift price targets in line with current expectations.내러티브 업데이트 • Dec 21
IPN: Guidance Upgrade And Competitive Pressures Will Shape A Cautious Yet Balanced Outlook
Analysts have reduced their price target on Ipsen from EUR 130.07 to EUR 105.00, citing increased competitive pressure on Somatuline as a key driver of the downgrade. Analyst Commentary Analysts note that the reduced price target reflects a reassessment of Ipsen's risk and reward profile in light of mounting competition for Somatuline, which is expected to weigh on both top line momentum and margin resilience.내러티브 업데이트 • Dec 07
IPN: Guidance Upgrade And Competition Concerns Will Shape Balanced Future Outlook
Analysts have trimmed their price target on Ipsen by approximately EUR 1 to around EUR 130, reflecting slightly lower long term growth and margin expectations amid rising competitive pressure on key drug Somatuline. Analyst Commentary Analyst sentiment around Ipsen has turned more cautious, with recent revisions reflecting heightened concern about the sustainability of growth in key endocrine oncology franchises and the implications for valuation.내러티브 업데이트 • Nov 22
IPN: Guidance Upgrade And New Approvals Will Support Balanced Outlook
Narrative Update on Ipsen Analysts have maintained their fair value estimate for Ipsen at €130.79 per share. They cite minimal changes in key assumptions and only slight fluctuations in projected growth and profitability.내러티브 업데이트 • Nov 07
IPN: Future Opportunities And Risks Are Balanced Following Guidance Upgrade
Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have raised their price target for Ipsen to €130.79, up from €129.93. This change reflects slight improvements in expected revenue growth and profit margin, despite a marginally higher discount rate.분석 기사 • Oct 28
Ipsen (EPA:IPN) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...내러티브 업데이트 • Oct 24
Global Approvals And Guidance Will Drive Expanded Patient Access Worldwide
Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have slightly increased their price target for Ipsen from $128.43 to $129.93. This adjustment is attributed to minor shifts in revenue growth forecasts and updated profit margin estimates.내러티브 업데이트 • Sep 25
Pipeline Catalysts And Approvals Will Expand Global Access
Driven by a modest uptick in consensus revenue growth forecasts and a slight increase in the projected future P/E, Ipsen’s analyst price target has inched up from €127.00 to €128.43. What's in the News Ipsen received Japanese regulatory approval for Bylvay (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC), with commercialization managed by Ipsen in Japan.분석 기사 • Sep 07
Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 41%?
Key Insights Ipsen's estimated fair value is €205 based on 2 Stage Free Cash Flow to Equity Current share price of €120...분석 기사 • Jul 13
Investors Interested In Ipsen S.A.'s (EPA:IPN) Earnings
Ipsen S.A.'s ( EPA:IPN ) price-to-earnings (or "P/E") ratio of 24.5x might make it look like a strong sell right now...
새로운 내러티브 • Feb 23
Cabometyx And Tovorafenib Approvals May Strengthen Oncology Portfolio In 2025
Expansion of Onivyde and new product approvals could significantly increase revenue and strengthen market positions in key medical segments.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | €444m |
| Sep 30 2025 | n/a | n/a | €446m |
| Jun 30 2025 | n/a | n/a | €448m |
| Mar 31 2025 | n/a | n/a | €402m |
| Dec 31 2024 | €5m | €1m | €356m |
| Jun 30 2024 | n/a | n/a | €664m |
| Mar 31 2024 | n/a | n/a | €641m |
| Dec 31 2023 | €4m | €988k | €617m |
| Jun 30 2023 | n/a | n/a | €406m |
| Mar 31 2023 | n/a | n/a | €500m |
| Dec 31 2022 | €4m | €950k | €593m |
| Sep 30 2022 | n/a | n/a | €656m |
| Jun 30 2022 | n/a | n/a | €719m |
| Mar 31 2022 | n/a | n/a | €675m |
| Dec 31 2021 | €5m | €950k | €631m |
| Sep 30 2021 | n/a | n/a | €626m |
| Jun 30 2021 | n/a | n/a | €622m |
| Mar 31 2021 | n/a | n/a | €585m |
| Dec 31 2020 | €5m | €475k | €548m |
보상 대 시장: David의 총 보수(USD5.55M)는 French 시장에서 비슷한 규모 기업의 평균(USD5.49M) 수준입니다.
보상과 수익: David의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
David Loew (58 yo)
5.8yrs
재임 기간
€4,772,278
보수
Mr. David Loew has been the Chief Executive Officer & MD of Ipsen S.A. since July 1, 2020, and serves as its Director since May 28, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| MD, CEO & Director | 5.8yrs | €4.77m | 0.11% € 13.7m | |
| Executive VP & CFO | 11.5yrs | €1.02m | 데이터 없음 | |
| Executive Vice President of Technical Operations | less than a year | 데이터 없음 | 데이터 없음 | |
| Global Vice President of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP & General Counsel | less than a year | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief Human Resources Officer | 8.2yrs | 데이터 없음 | 데이터 없음 | |
| Head of Nordics & Baltics | 9.1yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief Business Officer | 5.6yrs | 데이터 없음 | 데이터 없음 | |
| President of Fondation Ipsen | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP | 4.5yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief Medical Officer | 3yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP and Head of R&D | 2.7yrs | 데이터 없음 | 데이터 없음 |
5.0yrs
평균 재임 기간
55yo
평균 나이
경험이 풍부한 관리: IPN의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| MD, CEO & Director | 6yrs | €4.77m | 0.11% € 13.7m | |
| Non-Executive Chairman | 15.5yrs | €600.00k | 0.16% € 21.3m | |
| Independent Director | 8.9yrs | €118.20k | 0.00084% € 109.0k | |
| Director | 11yrs | €65.00k | 0.00061% € 79.2k | |
| Vice Chairman | 20.8yrs | €165.00k | 0.0037% € 473.8k | |
| Director | 20.8yrs | €45.00k | 26.57% € 3.4b | |
| Independent Director | no data | 데이터 없음 | 데이터 없음 | |
| Director | 13.9yrs | €115.00k | 0.00061% € 79.2k | |
| Director | 14.3yrs | €95.00k | 데이터 없음 | |
| Independent Director | 2.6yrs | €115.00k | 0.00061% € 79.2k | |
| Employees Representative Director | 5.5yrs | 데이터 없음 | 0.0016% € 212.9k | |
| Employee Representative Director | 4yrs | 데이터 없음 | 0.0042% € 546.5k |
11.0yrs
평균 재임 기간
61.5yo
평균 나이
경험이 풍부한 이사회: IPN의 이사회는 노련하고 경험이 풍부합니다(평균 재임 11 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/27 07:21 |
| 종가 | 2026/05/27 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Ipsen S.A.는 26명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |
| Yihan Li | Barclays |